Advancements in gene editing technology are boosting its adoption in various fields, including healthcare, diagnostics, agriculture, and industrial biotechnology.
• Immuno-oncology, blood disorders, and neuro-disorders are just a few of the diseases that gene editing technology targets. In addition, cardiovascular and viral diseases are intriguing areas that gene editing technology has the potential to treat.
• Most gene editing companies use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology for therapeutic and diagnostic development, mainly because CRISPR has the highest IP and is the most researched technology.
• Companies are actively working to overcome the challenges associated with CRISPR technology, which has resulted in the development of novel delivery technologies, new miniaturized Cas molecules, and nuclease expression control. All these advancements accelerate the adoption of gene editing technologies.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
